|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||18.50 - 19.61|
|52 Week Range||8.13 - 25.25|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||224.05|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||24.27|
BOULDER, CO, Aug. 21, 2019 /PRNewswire/ - (TSX: CWEB, OTCQX: CWBHF), Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company"), the market leader in whole-plant hemp CBD extract products is pleased to announce the results from its 2019 annual general and special meeting of shareholders held on August 20, 2019 in New York (the "Meeting"). Each of the matters voted upon at the Meeting is discussed in detail in the Company's Management Information Circular dated July 10, 2019 (the "Circular"), a copy of which is available on the Company's SEDAR profile at www.sedar.com. The total number of votes cast at the Meeting was 55,076,745, representing 56.57% of the total number of votes attached to the outstanding voting shares of the Company. The appointment of MNP LLP as the auditors of the Company to hold office until the close of the next annual meeting of shareholders of the Company.
Among marijuana stocks, very few have achieved profitability. But sooner or later, every company needs to reach that milestone.That sounds obvious, like "Business 101." In fact, it's one of the most basic requirements for a stock to trade on the "Big Board," the New York Stock Exchange (NYSE)… and also for the Nasdaq, for that matter.And yet, in the cannabis industry, Charlotte's Web (OTCMKTS:CWBHF) is one of the few that can deliver positive earnings! That's just one reason I want to put it on your radar today.InvestorPlace - Stock Market News, Stock Advice & Trading TipsCharlotte's Web was one of the original hemp-cannabidiol (CBD) companies, and perhaps the biggest success story of Colorado's legal cannabis boom. * 10 Stocks Under $5 to Buy for Fall CWBHF is also my pick for InvestorPlace's Best Stocks for 2019 contest - but really, it's among the top marijuana stocks for the next three years, at least, and here's why:With news Wednesday that the company's Q2 revenue rang in at $25 million, Charlotte's Web is expecting to post sales of $120-$170 million for the year. (At the midpoint, that puts the stock at a very attractive price-to-sales ratio of just 6X). But next year, analysts are expecting sales of $348 million… and $444 million the year after that.If that sounds lofty, keep in mind that Charlotte's Web CBD will soon be in twice as many stores as it was last year. From a niche product that was mainly found in health stores, you can now buy it at "big box" stores like CVS Health (NYSE:CVS) and, now, Kroger (NYSE:KR).The deal with Kroger, announced on July 31, is big; it adds 1,350 stores (in 22 states) to Charlotte's Web's retail network. The total number of retail locations carrying the company's products stood at 7,817 at the end of the quarter, up 1,926.Demand for hemp-CBD and this particular brand is booming, and to keep up, Charlotte's Web just expanded into the prestigious Colorado Technology Center, strategically located between the cities of Boulder and Denver.With the new location, Charlotte's Web will quadruple its footprint. After all, to make hemp-CBD, you've got to process a lot of hemp. And while operations will begin "early next year," the growth opportunity there will be just beginning.The Colorado Tech Center is better known for its tech startups, and Charlotte's Web is bringing some of that same energy to this expansion. Rather than resorting to CBD extraction techniques that are "decades old," their ambition is to use state-of-the-art technology to maintain what's always been the company's edge: "the highest-quality products."Here's another significant edge: reputation. The truth about the CBD market is that there are a lot of bad players - and those other guys will soon be removed by the coming wave of federal regulation. As I always say in Investment Opportunities, marijuana stocks are one group that needs regulators. And as a legitimate leader of the industry, Charlotte's Web will be the beneficiary.That's the context of the company's eye-catching earnings-per-share (EPS) projections. Already leading the pack with $0.27 per share expected this year, that should increase to $0.74 next year and $1.06 in 2021.The stock is up 65% since I picked it for the Best Stocks contest, even after it stumbled on Wednesday's quarterly report. But given these projections, CWBHF is still a steal as it trades around $20 on the over-the-counter (OTC) markets.As for the major stock exchanges - which open up a whole new world to companies like this - Charlotte's Web is on the right track to meet the NYSE and Nasdaq's earnings requirements for the long term. And I always believe in investing in a great stock early - BEFORE it makes that jump. Marijuana Stocks: Another "Jumper" Stock You Won't Want to MissGiven that it's fully legalized on its federal level, Canada is always a popular place to look for marijuana stocks, too. And one of my picks there just announced that it will "jump" to the Toronto Stock Exchange. (Charlotte's Web did, too, for that matter.)When a company moves to the big leagues, it opens up lots of doors for financing, offerings, and big institutional money. It's like the market's "seal of approval": an elite status with long-term benefits to the share price.In the next six to 12 months, I expect this particular Canadian stock to announce a second uplisting - to a U.S. exchange. That would be even more significant.Business wise, I'd put its extraction operation up against anyone's. At Investment Opportunities, you can get all the details on this and other up-and-coming cannabis stocks in the legalization mega-trend. Timing is EverythingEarly stage investing can be exciting… but also tricky.When a new industry booms - when billions of dollars are up for grabs - you can be sure all kinds of people will rush into the sector and try to get their share.Some of the companies will have smart, hardworking people running the show… great people to invest with. But, let me tell you, some of these folks aren't the kind of people you'd ever want to invite over for dinner… let alone do business with.That's a fact of life in any industry. But this challenge is magnified in a new industry with massive potential - like the legal marijuana industry.This is why it is critical to have a system… a framework for evaluating legal marijuana stocks.A path to profitability is certainly one of the things I look for here. But there's a little more to it than that!So, I created a 5-Factor Analytical Model for evaluating newly public legal marijuana companies to as part of my Cannabis Cash Calendar.I've put my model to the test in recent weeks to uncover my next Cannabis Cash Calendar recommendation… which I just released on Tuesday to my Investment Opportunities readers. But there is still time for you to get in on it, too, as it's still under my buy price!The opportunity in legal weed is much like the opportunity internet stocks offered in 1994… or that bitcoin offered in 2015. It is set to grow so much over the next 10 years that it will turn out to be one of the three biggest investment opportunities of your entire life - no matter when you were born.Click here to learn more and find out how you can get immediate access to my new recommendation.Matthew McCall is the founder and president of Penn Financial Group, an investment advisory firm, as well as the editor of Investment Opportunities and Early Stage Investor. He has dedicated his career to getting investors into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA), +1,044% in Tesla (TSLA), +611% in Liquefied Natural Gas Limited (LNGLY), +324% in Bitcoin Services (BTSC), just to name a few. If you're interested in making triple-digit gains from the world's biggest investment trends BEFORE anyone else, click here to learn more about Matt McCall and his investments strategy today. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Stocks Under $5 to Buy for Fall * 5 Stocks to Avoid Amid the Ongoing Trade War * 7 5G Stocks to Buy Now for the Future The post Marijuana Stocks: Catch the Next Hot Pot Stock Before It 'Jumps' appeared first on InvestorPlace.
The cannabidiol (CBD) leader returned to solid sequential revenue growth, but its spending soared even more than its sales did.
Charlotte’s Web Holdings, Inc. (OTC: CWBHF ) reported 45% year-over-year second-quarter revenue growth Wednesday. Gross margins for the quarter were 75.3%, with $18.8 million in gross profits. The whole-plant ...
The bumpy ride for Cronos (NASDAQ:CRON) stock investors continued this week when the cannabis stock got some more love from Wall Street. On Monday, Piper Jaffray analyst Micael Lavery initiated coverage of Cronos Group stock with an "outperform" rating and $18 price target.Lavery's initiation note was 29 pages long. However, the bull case for Cronos boils down to three main points.Source: ShutterstockInvestorPlace - Stock Market News, Stock Advice & Trading Tips CRON Stock Has a Big BrotherWhile other cannabis producers are out there trying to grow their business organically, Cronos has a perfect benefactor. In December 2018, tobacco giant Altria (NYSE:MO) invested $1.8 billion for a 45% stake in Cronos. In my opinion, the Altria partnership is the single biggest reason to consider CRON stock."We believe its partnership with Altria provides important capital ($1.8 billion cash) and access into 230,000 U.S. retail outlets, as well as regulatory and vapor product expertise," Lavery wrote. * 15 Growth Stocks to Buy for the Long Haul I would add two points to Lavery's case. U.S. (and potentially global) cigarette volumes are seemingly in secular decline. In other words, Altria needs Cronos as much as Cronos needs Altria. Tobacco companies are starving for growth. Cannabis could be a long-term lifeline.Second, Cronos Group stock investors hoping for U.S. cannabis legalization should realize one thing about their investment. They are investing in a tobacco company. As part of the terms of its 45% investment deal, Altria has the rights to take a full ownership stake at some point down the line.In my opinion, whether or not Altria exercises that option hinges on U.S. cannabis legalization. Without access to the U.S. market, Altria may not want to fully acquire Cronos. But if the U.S. ultimately legalizes weed on a federal level, I bet Altria's first move is a Cronos takeover.Progressive CRON stock investors may not like the idea of a tobacco takeover. But if the future of Altria is cannabis, at some point Altria is no longer a tobacco company at all. CBD Provides CRON Access to U.S. MarketAll cannabis stock investors know that U.S. federal marijuana legalization is the golden ticket. In the meantime, cannabidiol (CBD) may be the best way for Canadian producers like Cronos to get their foot in the U.S. door.CBD is a non-psychoactive, cannabis-derived chemical compound that was legalized in the U.S. in December 2018. The caveat is that only CBD produced from hemp, not marijuana, is legal. Lavery is expecting Cronos to use its $1.8 billion in Altria capital to launch a U.S. CBD strategy within the next year. In fact, he is projecting 60% of Cronos' 2020 revenue will come from CBD. Cronos Group's Brand AwarenessThe third big feather in Cronos Group's cap is its recent $300 million buyout of Redwood Holdings, parent company of early CBD brand leader Lord Jones.For millennial investors who are a fan of alternative data, Lavery included a cool statistic on Lord Jones in his note. Lord Jones alone has nearly 80,000 Instagram followers. That's more followers than the leading brands of popular cannabis stocks Tilray (NASDAQ:TLRY), Charlotte's Web Holdings (OTC:CWBHF) and Curaleaf Holdings (OTC:CURLF).It may seem like a trivial statistic, but social media popularity is an important measure of brand popularity. Marketing experts know brands are the key to success in untapped markets like the U.S. If Lord Jones becomes one of the gold standards in U.S. CBD, don't be surprised if Cronos/Altria markets its marijuana under the Lord Jones brand in the event of U.S. legalization. Understanding the Risks of CRON StockThe one thing I always try to include in my stories about cannabis stocks is a note about the risks involved in investing. There are so many uncertainties in the cannabis space right now. As if that weren't enough of a risk, cannabis stock valuations are sky-high, likely including at least some expected value from the U.S. marijuana market.Instead of rehashing points I've repeatedly made, here's Lavery's take:"We see a long runway of growth in the cannabis space, but valuation still has many speculative elements and can be very imprecise, given the early stages of the category and the myriad ways it could evolve," he wrote.Lavery makes some good points about buying CRON stock. However, any cannabis stock is a pure speculation at this time and these valuations. Don't invest any cash you wouldn't be comfortable losing in a worst-case scenario.As of this writing, Wayne Duggan did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 15 Growth Stocks to Buy for the Long Haul * 5 More Cloud Stocks With Plenty of Potential * 5 Clean Energy ETFs to Buy for 2019 The post 3 Reasons to Love Cronos Stock appeared first on InvestorPlace.
BOULDER, CO, Aug. 14, 2019 /PRNewswire/ - (TSX: CWEB, OTCQX: CWBHF), Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company"), the market leader in whole-plant hemp CBD extract products with naturally occurring cannabinoids, including cannabidiol ("CBD"), is pleased to announce that Russell Hammer has joined the Company as Chief Financial Officer, effective tomorrow, August 15, 2019. Mr. Hammer, who has most recently served as an advisor in private equity investments, brings more than 30 years of finance experience in the retail, tourism and technology sectors. With his experience leading multi-billion-dollar multinational companies, he is the latest top-tier executive to join Charlotte's Web as the Company accelerates its growth and evolution into a global consumer packaged goods ("CPG") brand.
BOULDER, CO , Aug. 8, 2019 /CNW/ - Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company") (TSX:CWEB, OTCQX:CWBHF), the market leader in hemp CBD extract products, announces expansion plans underway in 2019 including cultivation, production, distribution and R&D to support its forecasted sales growth. The new location enables the Company to prepare for production, distribution and R&D expansion to meet increasing demand from the consumer and national retailer channels. Charlotte's Web will commence a staged build-out of the facility during Q3-2019 and continuing over a two year period.
BOULDER, CO, July 31, 2019 /PRNewswire/ - Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company") (TSX:CWEB, OTCQX:CWBHF), the market leader in hemp CBD extract products, will issue its 2019 second quarter results on August 14 before the open of trading on the Toronto Stock Exchange. A conference call to discuss the results has been scheduled for the same day at 10:00 a.m. Eastern Time. To participate in the call, please dial 1-647-427-7450 or 1-888-231-8191 approximately 10 minutes before the conference call and provide conference ID 8685806. A recording of the call will be available through August 21, 2019. To listen to the rebroadcast please dial 1-416-849-0833 and provide the same conference ID.
Charlotte's Web (CWBHF) recently announced it added grocery giant Kroger (KR) to its growing list of retail outlets it will sell CBD products through. That will add another 1,350 outlets to its already impressive retail distributor base.Deanie Elsner, CEO of Charlotte's Web, said this about the deal:"Since its founding, Charlotte's Web has been on a mission to make CBD products available for as many people as possible. This distribution reach through Kroger's market leading network of grocery stores is an enormous contributor to our mission..."With Brightfield Group projecting CBD sales to soare to $22 billion by 2022, Charlotte's Web is positioning itself to take a nice chunk of that revenue.The biggest question concerning CBD to me is whether or not the estimated growth in sales is too optimistic, and expectations need to be lowered.CBD growth expectationsThe first thing to consider in regard to CBD growth expectations is if the $22 billion revenue projection is overly optimistic, within the short time frame it is expected to reach that level, which less than 30 months.Also important in relationship to Charlotte's Web is not only what percentage of that revenue it'll grab, but if it will be able to brand itself via a variety of CBD products to allow it to stand out in the minds of consumers. It's one thing for CBD sales to soar, it's another thing for a company to separate itself in the minds of consumers against their competitors. CBD could easily, in general, become a commodity market that competes primarily on price.That's why I remind investors continually that CBD should be considered similar to the vitamin and supplement markets. It's going to cater in some degree to the same type of customers, and since government entities like the FDA don't allow CBD products to be touted as cures or treatments for diseases, it makes it harder to pull away from the pack.That's why Charlotte's Web need to offer CBD products to the market based upon what consumers determine the value of specific products are to their health. That's how the vitamin and supplement markets work.Beyond compelling packaging, Charlotte's Web will have to find ways to convince consumers some of their CBD products are worth a higher price point.One way it is doing that is in the types of partners it will distribute through, such as Kroger. Even so, some of its competitors have done the same, so in going head-to-head with its major competitors, investors will need to identify how the company will differentiate from the plethora of products offered by a growing number of companies.Those best able to brand should be able to not only generate the most revenue, but also wider margins and stronger earnings, because consumers are willing to pay a premium for their products.Charlotte's Web's distribution reachWith the addition of Kroge to its distribution network, Charlotte's Web now has 5 major retailers it's distributing through, along with a number of specialty retailers. It now has a presence in over 8,000 U.S. locations it can distribute its CBD products through.In the Kroger universe, it will not only sell through the main grocery store bearing that name, but also via Dillons, Fred Meyer, King Soopers, Fry's, Mariano's, Pick 'n Save, QFC and Smith's, aka the Kroger Family of Stores.What's important isn't the number of distribution outlets is has, but the level it can leverage those locations to generate a profit. It also has yet to prove it will be able to sustainably grow revenue and earnings at the many stores it now will sell through.While the company claims it is "the most sought-after CBD brand," it's far too premature to make that claim. We're just in the very early stages of the CBD market, and it has yet to be determined who the long-term winners will be.ConclusionCharlotte's Web is positioned well to back up that assertion, but I believe the key will be which companies brand the best and are able to, for the most part, compete outside of the commodity CBD market.What I mean by that is in any retail market there will be loss leaders and low priced products to get consumers to try them out, with the purpose of getting them interested in trying out premium products.Word of mouth concerning the effect specific products have on various health conditions will be a big part of CBD winners, and that will have to come from feedback from consumers because of the restrictions by the FDA in the U.S. concerning making claims about healing and curing conditions.I believe there will be another part of the CBD market which after research and confirmed results, will open up a potential market similar to pharaceuticals. GW Pharmaceuticals and Epidiolex are the obvious example of that.If Charlotte's Web ever is able to offer those type of CBD products that are considered legitimate treatments by the FDA, it would have the potential to generate billions over time.But as the company stands today, it does have a strong foothold in the retail market, and if it is able to successfully differentiate itself from competitors, it has a strong growth trajectory ahead of it, even if the CBD market doesn't reach $22 billion in a couple of years.If it doesn't drop the ball, it should reward shareholders over the next few years at least.Charlotte's Web has a small, but vocal camp of bullish analysts with positive expectations for the stock. Out of the 3 analysts polled by TipRanks, all 3 rate the stock a Buy. With a return potential of 27%, the stock's 12-month consensus target price stands at C$29.50. (See Charlotte's Web's price targets and analyst ratings on TipRanks)
Charlotte’s Web Holdings (CWBHF) soared over 10% yesterday on news of a distribution deal with a major grocery chain. The landmines hitting the CBD and cannabis sector stocks suggest waiting for a pullback on the stock before loading up.Kroger DealOn Monday, the Boulder, CO based company announced a major distirbution deal with Kroger (KR), America’s largest grocery retailer. The deal involves CWB supplying hemp CBD extract products to their online site and 1,350 stores across 22 states making Kroger the largest single distribution deal.Based on this deal, CWB lists retail distribution that has now surpassed 8,000 locations. At the start of May, the company listed 6,000 locations. The company has now more than doubled their retail distribution network since the start of the yearThe announcement is very vague on the exact timing of reaching the full 1,350 stores owned by Kroger. The large grocery chain has over 2,700 retail locations so further expansion is possible and probable.A big reason the retail location ramp is important is that CWB only got 51% of revenues from retail locations in Q1. The company is still highly focused on their own online sales providing a massive ramp in revenues from only about $11 million in the last quarter.A big question remains how effective these mass retailers will be at selling CBD products. The shelves could become crowded with CBD products from competitors.CBD ProblemsThe cannabis sector has been under pressure in the last few months due to executive shakeups, audit frauds and FDA Warning Letters. The best time to buy the sector stocks lately has been on dips following these negative events. CWB stock surged over 10% for the day and hit $17 in initial trading. CWB is still down over $8 from the highs above $25 due to market weakness.CWB now has a market cap above $1.5 billion and isn’t likely to rally much beyond this level with revenue forecasts for 2019 at only $120 million to $170 million. The company reported Q1 revenues of ~$22 million and these deals with grocery chains like Kroger should boost revenues substantially above the low-end target. Although, the timing of a deal in July could push the majority of sales into next year.Analysts have CWB generating revenues of up to $350 million next year. The stock gets more reasonably priced when valued at about 4x 2020 revenue estimates.The market is rightfully concerned about the ability of CWB to achieve the 100%+ revenue gains in 2020. Combined with website statements that the FDA has not evaluated their statements on CBD products reducing stress and helping people recovery from exercise could suggest the company gets a similar warning letter from the FDA as Curaleaf (CURLF).TakeawayThe key investor takeaway is that Charlotte’s Web remains the best pure way to play the CBD craze in the U.S. market. The company now has the product on market and retail locations signed up for distribution. CWB should gain significant brand recognition over the Canadian companies that plan to enter the market in 2020 and beyond.The best way to own the stock for those without a current position is to wait for weakness in the sector or stock from something specific related to the FDA. CWB needs a lot to go right in order to reach 2020 revenue targets needed to justify higher stock prices.Overall, CWB has 2 bullish analysts in its corner over the last three months. The 12-month average price target of $25 implies about 50% in upside potential for the 'Moderate Buy' rated stock. (See CWB’s price targets and analyst ratings on TipRanks).
BOULDER, CO, July 30, 2019 /PRNewswire/ - Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company") (TSX:CWEB, OTCQX:CWBHF), the market leader in hemp CBD extract products, reports an extension of its research initiative with The Center for Discovery in New York State to further develop hemp genetics for optimal growing in the region. The groundbreaking project has been helping to solidify Charlotte's Web's expansion within the Eastern Appalachian Region by determining which hemp varieties grow the best under the regional microclimates and local terrain. Now in its third year, the initiative has steered Charlotte's Web's breeding program in the production of superior varieties that will support the efforts of local farmers and position the Company for success in New York and surrounding states with similar growing conditions.
BOULDER, CO, July 18, 2019 /PRNewswire/ - Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company") (TSX:CWEB, OTCQX:CWBHF), the market leader in hemp CBD extract products, has entered into a research initiative with Rodale Institute and Natural Care to pioneer regenerative organic hemp farming. The research will be conducted at Pocono Organics, a start-up regenerative organic farm in Long Pond, Pennsylvania. In alignment with its corporate social responsibility values, Charlotte's Web has been active in responsible farming practices since 2016.